Purple Biotech Ltd (PPBT): Price and Financial Metrics


Purple Biotech Ltd (PPBT): $1.89

0.09 (+4.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PPBT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PPBT Stock Price Chart Interactive Chart >

Price chart for PPBT

PPBT Price/Volume Stats

Current price $1.89 52-week high $4.28
Prev. close $1.81 52-week low $1.32
Day low $1.73 Volume 74,800
Day high $2.00 Avg. volume 46,022
50-day MA $1.66 Dividend yield N/A
200-day MA $2.25 Market Cap 33.24M

Purple Biotech Ltd (PPBT) Company Bio


Purple Biotech Ltd operates as a pharmaceutical company. The Company discovers and develops medicines, drugs, and other pharmaceutical products for the treatment of osteoarthritis pain and hypertension. Purple Biotech serves customers globally.


PPBT Latest News Stream


Event/Time News Detail
Loading, please wait...

PPBT Latest Social Stream


Loading social stream, please wait...

View Full PPBT Social Stream

Latest PPBT News From Around the Web

Below are the latest news stories about PURPLE BIOTECH LTD that investors may wish to consider to help them evaluate PPBT as an investment opportunity.

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Data demonstrate suppression by CM24 of NET-promoting cancer cell migration and metastasis Findings suggest potential new treatment target for metastasis REHOVOT, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it is

Yahoo | November 15, 2022

Purple Biotech to Present at the Jefferies London Healthcare Conference

REHOVOT, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that Gil Efron, Chief Executive Officer of Purple Biotech, and Fabien Sebille, Chief Business Officer, will present a corporate overview of the Co

Yahoo | November 10, 2022

Purple Biotech Reports Third Quarter 2022 Financial Results

Well capitalized with cash runway through 2024 Clinical progress for both programs, CM24 and NT219 REHOVOT, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter ended September 30, 2022

Yahoo | November 8, 2022

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Seasoned financial executive strengthens management team REHOVOT, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Lior Fhima, CPA, MBA, as Chief Financial Officer of the Company. Mr. Fhima brings deep

Yahoo | November 2, 2022

Purple Biotech (PPBT) Gets a Buy from H.C. Wainwright

In a report released today, Emily Bodnar from H.C. Wainwright initiated coverage with a Buy rating on Purple Biotech (PPBT - Research Report) and a price target of $7.00. The company's shares closed last Friday at $1.98.According to TipRanks, Bodnar is an analyst with an average return of -11.9% and a 24.32% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Imunon, Context Therapeutics, and Dice Therapeutics.Purple Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.See the top stocks recommended by analysts >>The company has a one-year high of $4.75 and a one-year low of $1.83.

Carrie Williams on TipRanks | October 17, 2022

Read More 'PPBT' Stories Here

PPBT Price Returns

1-mo 36.96%
3-mo -9.57%
6-mo -24.70%
1-year -27.31%
3-year -74.01%
5-year N/A
YTD 36.96%
2022 -64.52%
2021 2.10%
2020 -51.13%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6175 seconds.